GLP-1 Therapy and OSA: Promise, But Limits
Reported by Medscape. Read the original →
The headline suggests that there is potential for GLP-1 therapy in relation to obstructive sleep apnea (OSA), but also indicates that there are limitations to this approach. The specifics of the promise and the nature of the limits are not provided.
Summarised by a model from Medscape's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.
On file here
Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.
14 compounds tracked · 344 studies on file · 150 in humans
What the headline doesn't tell you
- This story is about a class — GLP-1 and incretin therapies — rather than one compound. We track 14 compounds in it, holding 344 studies between them, 150 in humans.
Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.